Algeria Pharmaceutical Import & Registration Guide

Ministry of Health: The Regulator

The Algerian Ministry of Health (Ministère de la Santé) is the national health authority. The Direction de la Pharmacie et des Équipements Médicaux (DPEM) is responsible for pharmaceutical regulation, including product registration, import controls, and market surveillance.

MOH's core functions:

• Product registration and marketing authorization
• Inspecting manufacturing facilities (GMP audits)
• Issuing import and export permits
• Pharmacovigilance and post-market surveillance
• Clinical trial authorization
• Pricing approval and regulation
• Managing import quotas and local manufacturing preferences

MOH is headquartered in Algiers, with a partially digitized submission system. French is the working language—all submissions must be in French. English submissions are not accepted.

Registration Pathways & Product Categories

Algeria offers several registration pathways, with strong preferences for locally manufactured products.

Pathway 1: Full Registration (New Chemical Entities / NCEs)

Full clinical trial data required. Timeline: 12-18 months. Algeria is a significant market for innovative products.

Pathway 2: Abridged Registration (Generic Products)

Requires bioequivalence data. This is the most common pathway for imports. Timeline: 10-15 months.

Pathway 3: Locally Manufactured Products (Fast-Track)

Products manufactured in Algeria receive priority processing (4-8 months) and significant tender preferences. This is the strategic pathway.

Pathway 4: WHO PQ Recognition

Products with WHO Prequalification receive priority review. Timeline: 6-9 months.

Pathway 5: SRA Recognition

Products approved by US FDA, EMA, ANSM (France), or other SRAs receive accelerated review. Timeline: 6-10 months.

Prerequisites: What You Need Before Applying

Before submitting to the Algerian MOH, ensure these items are in place.

• Appoint a Local Agent/Distributor: Foreign manufacturers must appoint an Algerian company with a valid MOH import license. The agent will hold the registration.
• Execute a Power of Attorney (PoA): A notarized document authorizing your local agent. Must be legalized at the Algerian embassy and translated into French.
• Obtain a Certificate of Pharmaceutical Product (CPP): Issued by your home regulator. Must be in WHO format, less than 2 years old, legalized, and translated into French.
• Prepare Your Dossier in CTD Format: MOH follows CTD format. All documents must be in French.
• Bioequivalence Study (for generics): Must be conducted at a recognized center (WHO PQ or SRA-recognized).
• Product Samples: Required for MOH laboratory testing in Algiers.

Step-by-Step Registration Process

Here's the actual process for registering with the Algerian MOH. Be prepared for bureaucracy and delays.

Step 1: Appoint a Local Agent

Sign an agreement with an Algerian importer. Verify their MOH license and their experience with product registration and tenders.

Step 2: Execute and Legalize Power of Attorney

Draft PoA, notarize, legalize at Algerian embassy, translate to French. This takes 4-6 weeks.

Step 3: Prepare Your French CTD Dossier

Compile CTD dossier (Modules 1-5) in French. All documents must be translated and certified.

Step 4: Pre-Submission Consultation (Recommended)

Your agent can request a meeting with MOH evaluators. Highly recommended to understand current requirements.

Step 5: Submission to MOH

Your agent submits the dossier (paper copies, as digitization is limited), pays the application fee (DZD 50,000-150,000/$370-1,100), and receives an acknowledgement.

Step 6: Administrative Screening (4-8 weeks)

MOH checks for completeness, legalization, French translations, and format. Deficiency letters add 4-8 weeks per cycle.

Step 7: Scientific Evaluation (8-12 months)

MOH evaluators review quality, bioequivalence (if applicable), and labeling. Queries are communicated via your agent. You have 60-90 days to respond.

Step 8: Laboratory Testing (2-4 months)

MOH's National Laboratory for Drug Control (LNCM) in Algiers tests product samples. Failure = rejection.

Step 9: GMP Inspection (If Required)

MOH accepts WHO PQ, SRA inspections, or their own inspection. Local manufacturing waives import inspection.

Step 10: Pricing Approval (2-4 months)

MOH sets the maximum selling price. See pricing section below.

Step 11: MOH Registration Commission Approval (6-8 weeks)

Final approval and certificate issuance.

Dossier Requirements: The CTD Format

Algeria follows CTD format (Modules 1-5) in French.

Module 1: Administrative Information (Algeria-Specific)

• Application letter on manufacturer letterhead (French)
• Cover letter from Algerian agent (French)
• Power of Attorney (legalized, French translation)
• Certificate of Pharmaceutical Product (WHO format, legalized, French, less than 2 years old)
• GMP Certificate (legalized, French)
• Free Sale Certificate (French)
• Manufacturing license (French)
• Labeling and package insert (French)
• WHO PQ certificate or SRA approval (if available)

Module 2: Summaries (French)

Module 3: Quality (French)

• Stability data: Algeria has a Mediterranean climate on the coast and desert climate inland. Zone III/IV data recommended.

Module 4: Nonclinical (NCEs only - French)

Module 5: Clinical/Bioequivalence (French)

Local Agent Requirements: The Mandatory Local Representative

Algeria's local agent requirements are strict and non-negotiable.

What Your Algerian Agent Must Have:

• Valid MOH pharmaceutical import license (must be renewed annually)
• Physical warehouse in Algiers or other major city (Oran, Constantine, Annaba)
• Qualified pharmacist on staff (pharmacien responsable)
• Experience with MOH registration and public tender participation
• Cold chain capability (for temperature-sensitive products)
• Ability to navigate complex administrative procedures

Selecting Your Agent:

• Algeria has approximately 20-30 licensed pharmaceutical importers
• Key players include: Saidal (state-owned), Biopharm, Pharmalliance, New Pharma, and various private importers
• Saidal (the state-owned manufacturer/distributor) dominates the market and has preferential access to tenders
• Choose an agent with strong government relationships and tender experience

Local Manufacturing Requirements: The 50% Rule

This is the most important section for understanding Algeria's market.

The 50% Rule:

Algerian law requires that 50% of the value of public pharmaceutical tenders be allocated to locally manufactured products. This means:

• If your product is imported only, you can only compete for 50% of tender volume
• Locally manufactured products receive significant price preferences (10-20% higher than imports)
• For some therapeutic categories, imports may be completely restricted

Local Manufacturing Options:

1. Joint Venture with Algerian manufacturer: Most common route. Partner with Saidal or a private Algerian manufacturer. They produce locally, you supply API and technology. Minimum investment: $5-15 million.
2. Technology transfer to existing manufacturer: License your product to an Algerian manufacturer for local production. Lower investment ($1-5 million), but you lose direct control.
3. Wholly-owned facility: Build your own manufacturing plant. High investment ($20-50+ million). Requires significant commitment.

Strategic Implications:

• Pure import models are increasingly disadvantaged
• Local manufacturing (or partnership) is essential for significant market access
• The government actively seeks technology transfer and local production partnerships

Import Restrictions & Quotas

Algeria has significant import restrictions that affect pharmaceutical exporters.

Import Quotas:

• The Ministry of Health sets annual import quotas for each therapeutic category
• Quotas are allocated to registered importers based on previous performance and local manufacturing commitments
• If a product is manufactured locally, imports may be completely restricted

Import Licensing:

• Each import shipment requires a specific import permit from MOH
• Permits take 2-6 weeks to obtain
• Importers must demonstrate that the product is not available from local manufacturers

Products Subject to Import Restrictions:

• Antibiotics (significant local manufacturing capacity)
• Essential medicines on the national list
• Chronic disease medications (diabetes, hypertension)
• Generic versions of products made locally

The Tender System: Public Procurement

Algeria's public sector pharmaceutical procurement is centralized through the National Agency for Pharmaceutical Products (ANPP) and the National Health Insurance Fund (CNAS).

How Tenders Work:

1. MOH/ANPP issues tender announcements (typically quarterly).
2. Eligible suppliers (registered importers with MOH-registered products) submit bids in French.
3. The Tender Committee evaluates bids based on:
   • Price (50-60% weight) - Lowest price is heavily weighted
   • Local manufacturing status (20-30% weight) - Locally manufactured products receive significant preference
   • Product quality (20% weight) - WHO PQ preferred
   • Supplier reliability (10% weight)
4. By law, 50% of tender value must go to locally manufactured products.
5. Winning bids receive contracts for specific quantities, delivered to ANPP central warehouses.

Private Sector Opportunity:

The private sector accounts for only 20-30% of the Algerian pharmaceutical market. Private pharmacies and hospitals purchase registered products through distributors, but volumes are limited.

Pricing Regulations: The Lowest Price Principle

Algeria has aggressive pricing regulations that favor low-cost generics.

How Pricing Works:

1. After scientific approval, your agent submits a pricing application to MOH.
2. You propose a Maximum Selling Price (MSP).
3. MOH reviews your proposal against:
   • Lowest price in reference countries (Egypt, Tunisia, Morocco, Jordan)
   • Prices of similar products in Algeria
   • Manufacturing cost + reasonable margin (limited weight)
4. MOH approves an MSP—typically very low.

Key Pricing Realities:

• Algeria has some of the lowest pharmaceutical prices in the region. Prices are comparable to Egypt, lower than Morocco and Tunisia.
• Generics must be priced 30-40% below originators.
• Prices are fixed for 5 years. Increases require re-approval and are rare.
• Local manufacturing does not guarantee higher prices. The government uses international reference pricing regardless of origin.

GMP Compliance & Facility Inspections

Algeria's GMP requirements are aligned with WHO GMP and European standards (influenced by French regulation).

GMP Evidence MOH Accepts:

• WHO Prequalification (highest acceptance)
• ANSM (France) inspection (strongly preferred due to historical ties)
• EMA or other SRA inspection
• MOH-conducted inspection

When Does MOH Conduct Its Own Inspection?

• First-time registration without WHO PQ or SRA evidence
• Local manufacturing facilities (mandatory)
• High-risk products (injectables, biologics)

Inspection Process:

1. MOH notifies your agent (8-12 weeks notice)
2. Fee: $8,000-15,000 plus travel expenses
3. Inspectors visit for 3-5 days
4. CAPA plan required for findings

Costs, Timelines & Budget Planning

Algeria has moderate official fees but significant hidden costs and long timelines.

Official MOH Fees (Approximate)

• Application fee: DZD 50,000-150,000 ($370-1,100)
• Evaluation fee: DZD 100,000-300,000 ($740-2,200)
• Registration certificate: DZD 50,000-100,000 ($370-740)
• Annual retention fee: DZD 30,000-80,000 ($220-590) per product

Third-Party Costs

• Regulatory consultant fees: $15,000-35,000 per product
• French translation & certification: $3,000-8,000
• Document legalization: $2,000-4,000
• GMP inspection (if required): $10,000-18,000 plus travel
• Bioequivalence study: $50,000-150,000 if new study needed
• Stability studies: $10,000-25,000
• Local agent fees: $10,000-25,000 annually
• Local manufacturing partnership (if pursued): $1-15 million

Total Estimated Cost Per Product:

• Generic with WHO PQ (import): $25,000-45,000
• Generic with SRA approval (import): $30,000-50,000
• Standard generic (import, well-prepared): $35,000-60,000
• Standard generic (with new BE study): $80,000-150,000
• Local manufacturing partnership: $1,000,000-15,000,000 (one-time investment)

Timelines:

• WHO PQ Fast-Track: 6-9 months
• SRA Fast-Track: 6-10 months
• Standard generic (well-prepared): 10-15 months
• Standard generic (poor dossier, delays): 15-24 months
• Local manufacturing (fast-track): 4-8 months

Currency & Forex Challenges

This is a critical risk factor for Algeria.

Key Forex Realities:

• Official vs. parallel market: Official rate is approximately 135 DZD/USD, but the parallel market exceeds 200-220 DZD/USD. Your effective revenue in USD may be much lower than expected.
• Forex availability: Importers often face delays (3-6 months) in obtaining USD from banks to pay foreign suppliers.
• Government payment delays: Public tender payments can take 6-12 months after delivery.
• Repatriation challenges: Getting profits out of Algeria in USD is difficult.

Mitigation Strategies:

• Price in USD in your supply agreement, but accept DZD payment
• Build forex risk into your pricing (expect 30-40% currency loss)
• Work with a local agent who has strong banking relationships
• Consider local manufacturing to reduce import forex needs
• Use a European or Dubai-based intermediary for settlements

Common Pitfalls & Rejection Reasons

• Documents Not in French: English submissions are rejected outright
• Invalid or Expired CPP: Less than 2 years old, WHO format required
• Missing Legalization: All foreign documents must be legalized at Algerian embassy
• Missing French Translations: All documents must have certified French translations
• Incorrect Reference Product for BE: Must use Algeria-registered reference
• Inadequate Stability Data: Appropriate climate zone data required
• GMP Certificate Issues: Expired or not from recognized authority
• No Local Agent Agreement: Valid agent license must be on file
• Product Sample Fails LNCM Testing: Immediate rejection
• Unreasonable Pricing Proposal: Too high compared to reference countries
• No Import Quota: Even with registration, you may not get import quota

Post-Registration Obligations & Renewal

• Annual Retention Fees: Payable each year
• Variations: Changes require MOH approval; timeline 4-8 months
• Renewal: Every 5 years, start 12 months before expiry
• Pharmacovigilance: Your agent must report adverse events; PSURs every 2 years
• Import Quota Management: Annually secure quota allocations
• Post-Market Surveillance: MOH samples products; failures lead to recalls
• Local manufacturing compliance: If manufacturing locally, annual GMP inspections

Conclusion: Your Algeria Entry Strategy

Algeria is a large, wealthy market with significant opportunities—but also the most protectionist in North Africa. The 50% local manufacturing rule, import quotas, low prices, and forex challenges make it a difficult market for pure importers.

Your Algeria registration checklist:

• ✓ Find an Algerian agent with MOH license, import quota, and tender experience
• ✓ Consider a local manufacturing partnership (essential for significant market access)
• ✓ Obtain WHO PQ or SRA approval (ANSM preferred) for your product
• ✓ Execute and legalize Power of Attorney with French translation
• ✓ Obtain valid CPP (WHO format, less than 2 years old)
• ✓ Prepare CTD dossier in French (professional translation required)
• ✓ Budget $35,000-60,000 per product for import ($1-15M for local manufacturing)
• ✓ Plan for 10-15 months for registration (6-10 months with SRA/WHO PQ)
• ✓ Develop ultra-competitive pricing (Algeria has very low prices)
• ✓ Build forex risk into your pricing (30-40% currency impact)
• ✓ Plan for import quota allocation annually
• ✓ Hire an Algerian regulatory consultant with MOH and ANPP relationships
• ✓ Be patient—Algeria's bureaucracy is challenging

Is Algeria worth it? For manufacturers with a low-cost base, WHO PQ/SRA approval, and a local manufacturing partner, yes. The market is large (45 million people, $3-4 billion), and the government is committed to healthcare expansion. For pure importers without local manufacturing, the barriers are increasingly prohibitive.

Algeria is a long-term commitment. Registering is just the first step—securing import quotas, winning tenders, and managing forex challenges require ongoing effort. But for those who can navigate the complexities, Algeria offers substantial volume and strategic positioning in North Africa.